Skip to main content
Top
Published in: Endocrine 1/2010

01-08-2010 | Original Article

Heparanase-1 and Cyclooxygenase-2: prognostic indicators of malignancy in pheochromocytomas

Authors: Yu Zhu, Hong-chao He, Fei Yuan, Jun Zhang, Wen-bin Rui, Ju-ping Zhao, Zhou-jun Shen, Guang Ning

Published in: Endocrine | Issue 1/2010

Login to get access

Abstract

The objective of this article is to evaluate Heparanase-1 and Cyclooxygenase-2 as tissue-based markers of pheochromocytoma prognosis. Ninety-two sporadic pheochromocytoma patients with a minimum of 8-year follow-up post-diagnosis were enrolled. Slides of normal adrenal glands in nephrectomy specimens from 20 patients with benign renal tumors were as control. Heparanase-1 and Cyclooxygenase-2 expression as well as microvessel density were examined using immunohistochemistry in tissues from these patients. Positive staining for Heparanase-1 was observed in 23.68% of the benign and 77.78% of the malignant cases, whereas none of the normal adrenal controls showed positive staining. Similarly, Cyclooxygenase-2 staining was seen in 23.68% of the benign versus 83.33% of the malignant cases, and none of the normal controls appeared positive for Cyclooxygenase-2. Using both HPA-1 and Cox-2 combined, the positive predictive value of malignancy was significantly increased to 0.72, compared to about 0.45 by their own. Malignant cases showed higher microvessel density compared to benign tumors and normal controls (36.41, 21.43, and 13.36%, respectively). Heparanase-1 and Cyclooxygenase-2 may contribute to the invasive characteristics of malignant pheochromocytomas. Heparanase-1 and Cyclooxygenase-2 combined is better than their own to be used as a marker to distinguish malignant from benign pheochromocytoma.
Literature
1.
go back to reference G. Eisenhofer, S.R. Bornstein, F.M. Brouwers et al., Malignant pheochromocytoma: current status, initiatives for future progress. Endocr. Relat. Cancer 11, 423–436 (2004)CrossRefPubMed G. Eisenhofer, S.R. Bornstein, F.M. Brouwers et al., Malignant pheochromocytoma: current status, initiatives for future progress. Endocr. Relat. Cancer 11, 423–436 (2004)CrossRefPubMed
2.
go back to reference R.I. Linnoila, H.R. Keiser, S.M. Steinberg, E.E. Lack, Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum. Pathol. 21, 1168–1180 (1999)CrossRef R.I. Linnoila, H.R. Keiser, S.M. Steinberg, E.E. Lack, Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum. Pathol. 21, 1168–1180 (1999)CrossRef
3.
go back to reference E.E. Lack, Adrenal medullary hyperplasia and pheochromocytoma, in Pathology of the Adrenal Glands, ed. by E.E. Lack (Churchill Livingstone, New York, 1990), pp. 173–235 E.E. Lack, Adrenal medullary hyperplasia and pheochromocytoma, in Pathology of the Adrenal Glands, ed. by E.E. Lack (Churchill Livingstone, New York, 1990), pp. 173–235
4.
go back to reference M. Toyoshima, M. Nakajima, Human heparanase: purification, characterization, cloning, expression. J. Biol. Chem. 274, 24153–24160 (1999)CrossRefPubMed M. Toyoshima, M. Nakajima, Human heparanase: purification, characterization, cloning, expression. J. Biol. Chem. 274, 24153–24160 (1999)CrossRefPubMed
5.
go back to reference R.M. Quiros, A.W. Kim, J. Maxhimer, P. Gattuso, X. Xu, R.A. Prinz, Differential heparanase-1 expression in malignant, benign pheochromocytoma. J. Surg. Res. 108, 44–50 (2002)CrossRefPubMed R.M. Quiros, A.W. Kim, J. Maxhimer, P. Gattuso, X. Xu, R.A. Prinz, Differential heparanase-1 expression in malignant, benign pheochromocytoma. J. Surg. Res. 108, 44–50 (2002)CrossRefPubMed
6.
go back to reference K. Merati, M. said Siadaty, A. Andea et al., Expression of inflammatory modulator CoX-2 in pancreatic ductal adenocarcinoma, its relationship to pathologic, clinical parameters. Am. J. Clin. Oncol. 24, 447–452 (2001)CrossRefPubMed K. Merati, M. said Siadaty, A. Andea et al., Expression of inflammatory modulator CoX-2 in pancreatic ductal adenocarcinoma, its relationship to pathologic, clinical parameters. Am. J. Clin. Oncol. 24, 447–452 (2001)CrossRefPubMed
7.
go back to reference N. Weidner, Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol. 147, 9–19 (1995)PubMed N. Weidner, Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol. 147, 9–19 (1995)PubMed
8.
go back to reference H.C. Klingler, P.J. Klingler, J.K. Martin Jr., R.C. Smallridge, S.L. Smith, R.A. Hinder, Pheochromocytoma. Urology 57, 1025–1032 (2001)CrossRefPubMed H.C. Klingler, P.J. Klingler, J.K. Martin Jr., R.C. Smallridge, S.L. Smith, R.A. Hinder, Pheochromocytoma. Urology 57, 1025–1032 (2001)CrossRefPubMed
9.
go back to reference I. Vlodavsky, Y. Friedmann, M. Elkin et al., Mammalian heparanase: gene cloning, expression, function in tumor progression, metastasis. Nat. Med. 5, 793–802 (1999)CrossRefPubMed I. Vlodavsky, Y. Friedmann, M. Elkin et al., Mammalian heparanase: gene cloning, expression, function in tumor progression, metastasis. Nat. Med. 5, 793–802 (1999)CrossRefPubMed
10.
go back to reference M.D. Hulett, C. Freeman, B.J. Hamdorf, R.T. Baker, M.J. Harris, C.R. Parish, Cloning of mammalian heparanase, an important enzyme in tumor invasion, metastasis. Nat. Med. 5, 803–809 (1999)CrossRefPubMed M.D. Hulett, C. Freeman, B.J. Hamdorf, R.T. Baker, M.J. Harris, C.R. Parish, Cloning of mammalian heparanase, an important enzyme in tumor invasion, metastasis. Nat. Med. 5, 803–809 (1999)CrossRefPubMed
11.
go back to reference A. Koliopanos, H. Friess, J. Kleeff et al., Heparanase expression in primary, metastatic pancreatic cancer. Cancer Res. 61, 4655–4659 (2001)PubMed A. Koliopanos, H. Friess, J. Kleeff et al., Heparanase expression in primary, metastatic pancreatic cancer. Cancer Res. 61, 4655–4659 (2001)PubMed
12.
go back to reference K. Gohji, H. Hirano, M. Okamoto et al., Expression of three extracellular matrix degradative enzymes in bladder cancer. Int. J. Cancer 95, 295–301 (2001)CrossRefPubMed K. Gohji, H. Hirano, M. Okamoto et al., Expression of three extracellular matrix degradative enzymes in bladder cancer. Int. J. Cancer 95, 295–301 (2001)CrossRefPubMed
13.
go back to reference A. Ferrandez, S. Prescott, R.W. Burt, CoX-2, colorectal cancer. Curr. Pharm. Des. 9, 2229–2251 (2003)CrossRefPubMed A. Ferrandez, S. Prescott, R.W. Burt, CoX-2, colorectal cancer. Curr. Pharm. Des. 9, 2229–2251 (2003)CrossRefPubMed
14.
go back to reference D. Brattström, K. Wester, M. Bergqvist et al., HER-2, EGFR, CoX-2 expression status correlated to microvessel density, survival in resected non-small cell lung cancer. Acta Oncol. 43, 80–86 (2004)CrossRefPubMed D. Brattström, K. Wester, M. Bergqvist et al., HER-2, EGFR, CoX-2 expression status correlated to microvessel density, survival in resected non-small cell lung cancer. Acta Oncol. 43, 80–86 (2004)CrossRefPubMed
15.
go back to reference B.S. Sheu, H.B. Yang, S.M. Sheu, A.H. Huang, J.J. Wu, Higher gastric cycloxygenase-2 expression, precancerous change in Helicobacter pylori-infected relatives of gastric cancer patients. Clin. Cancer Res. 9, 5245–5251 (2003)PubMed B.S. Sheu, H.B. Yang, S.M. Sheu, A.H. Huang, J.J. Wu, Higher gastric cycloxygenase-2 expression, precancerous change in Helicobacter pylori-infected relatives of gastric cancer patients. Clin. Cancer Res. 9, 5245–5251 (2003)PubMed
16.
go back to reference G.S. Gupta, M. Srivastava, N. Ahmad, D.G. Bostwick, H. Mukhtar, Over expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42, 73–78 (2001)CrossRef G.S. Gupta, M. Srivastava, N. Ahmad, D.G. Bostwick, H. Mukhtar, Over expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42, 73–78 (2001)CrossRef
17.
go back to reference R. Yoshimura, H. Sano, M. Mitsuhashi, M. Kohno, J. Chargui, S. Wada, Expression of cyclooxygenase-2 in patients with bladder carcinoma. J. Urol. 165, 1468–1472 (2001)CrossRefPubMed R. Yoshimura, H. Sano, M. Mitsuhashi, M. Kohno, J. Chargui, S. Wada, Expression of cyclooxygenase-2 in patients with bladder carcinoma. J. Urol. 165, 1468–1472 (2001)CrossRefPubMed
18.
go back to reference R. Yoshimura, M. Matsuyama, Y. Kawahito et al., Study of cyclooxygenase-2 in renal cell carcinoma. Int. J. Mol. Med. 13, 229–233 (2004)PubMed R. Yoshimura, M. Matsuyama, Y. Kawahito et al., Study of cyclooxygenase-2 in renal cell carcinoma. Int. J. Mol. Med. 13, 229–233 (2004)PubMed
19.
go back to reference K. Saukkonen, J. Rintahaka, A. Sivula et al., Cyclooxygenase-2, gastric carcinogenesis. APMIS 111, 915–925 (2003)CrossRefPubMed K. Saukkonen, J. Rintahaka, A. Sivula et al., Cyclooxygenase-2, gastric carcinogenesis. APMIS 111, 915–925 (2003)CrossRefPubMed
20.
go back to reference K. Salmenkivi, C. Haglund, A. Ristimäki, J. Arola, P. Heikkilä, Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J. Clin. Endocrinol. Metab. 86, 5615–5619 (2001)CrossRefPubMed K. Salmenkivi, C. Haglund, A. Ristimäki, J. Arola, P. Heikkilä, Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J. Clin. Endocrinol. Metab. 86, 5615–5619 (2001)CrossRefPubMed
21.
go back to reference J.B. Laforga, F.I. Aranda, Angiogenic index: a new method for assessing microvascularity in breast carcinoma with possible prognostic implications. Breast J. 6, 103–107 (2000)CrossRefPubMed J.B. Laforga, F.I. Aranda, Angiogenic index: a new method for assessing microvascularity in breast carcinoma with possible prognostic implications. Breast J. 6, 103–107 (2000)CrossRefPubMed
22.
go back to reference M. Elkin, N. Ilan, R. Ishai-Michaeli et al., Heparanase as mediator of angiogenesis: mode of action. FASEB J. 15, 1661–1663 (2001)PubMed M. Elkin, N. Ilan, R. Ishai-Michaeli et al., Heparanase as mediator of angiogenesis: mode of action. FASEB J. 15, 1661–1663 (2001)PubMed
23.
go back to reference T. Imada, J. Matsuoka, T. Nobuhisa et al., CoX-2 induction by heparanase in the progression of breast cancer. Int. J. Mol. Med. 17, 221–228 (2006)PubMed T. Imada, J. Matsuoka, T. Nobuhisa et al., CoX-2 induction by heparanase in the progression of breast cancer. Int. J. Mol. Med. 17, 221–228 (2006)PubMed
24.
go back to reference T. Okawa, Y. Naomoto, T. Nobuhisa et al., Heparanase is involved in angiogenesis in esophageal cancer through induction of cyclooxygenase-2. Clin. Cancer Res. 11, 7995–8005 (2005)CrossRefPubMed T. Okawa, Y. Naomoto, T. Nobuhisa et al., Heparanase is involved in angiogenesis in esophageal cancer through induction of cyclooxygenase-2. Clin. Cancer Res. 11, 7995–8005 (2005)CrossRefPubMed
25.
go back to reference Y. Ohtawa, Y. Naomoto, Y. Shirakawa et al., The close relationship between heparanase, cyclooxygenase-2 expressions in signet-ring cell carcinoma of the stomach. Hum. Pathol. 37, 1145–1152 (2006)CrossRefPubMed Y. Ohtawa, Y. Naomoto, Y. Shirakawa et al., The close relationship between heparanase, cyclooxygenase-2 expressions in signet-ring cell carcinoma of the stomach. Hum. Pathol. 37, 1145–1152 (2006)CrossRefPubMed
Metadata
Title
Heparanase-1 and Cyclooxygenase-2: prognostic indicators of malignancy in pheochromocytomas
Authors
Yu Zhu
Hong-chao He
Fei Yuan
Jun Zhang
Wen-bin Rui
Ju-ping Zhao
Zhou-jun Shen
Guang Ning
Publication date
01-08-2010
Publisher
Springer US
Published in
Endocrine / Issue 1/2010
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-010-9356-y

Other articles of this Issue 1/2010

Endocrine 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine